Abstract library

106 results for "systemic inflammation".
#2115 Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials
Introduction: NETs are extremely heterogeneous in nature. Despite recent advances, few biomarkers are available to consistently predict prognosis and optimize treatment selection.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: David L Chan
#1893 Peripheral Blood Biomarkers of Systemic Inflammation May Be Prognostic in Metastatic Gastroenteropancreatic Neuroendocrine Tumour (GEPNET) Patients Following 177Lu-DOTATATE (LuTate)
Introduction: LuTate is a treatment for well-differentiated NETs with adequate somatostatin receptor expression. Prognostic biomarkers in this population are lacking. Neutrophil-to-lymphocyte ratio (NLR) is prognostic in the majority of solid tumours but is reported to have less value in indolent well-differentiated NETs.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Dr Aimee Hayes
#1026 Systemic Therapy in Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) and Ki Index 5-10%
Introduction: Phase III trials of sunitinib, everolimus and octreotide lar confirmed that these drugs improved progression-free survival (PFS) in well-differentiated PNET, low/intermediate grade pNET and well-differentiated midgut NETs, respectively. CLARINET is the 1st phase III study that showed PFS benefit of SSA, lanreotide, in both P- and midgut NET and in Ki-67 5-10%.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: PhD Paula J Fonseca
#1311 Blood-Based Prognostic Biomarkers in Neuroendocrine Tumour: A Retrospective Study
Introduction: Markers of systemic inflammation –such as the neutrophil:lymphocyte ratio (NLR), platelet:lymphocyte ratio (PLR) and lymphocyte:monocyte ratio (LMR) - have been shown to correlate with poor prognosis in multiple solid organ tumours. Analysis of CLARINET showed no significant association between NLR and progression-free survival.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr David Chan
Authors: Diakos C, Chan D, Gurney E, Bailey D, ...
Keywords: NLR, biomarker
#1740 A Nomogram Consisted of Routine Biochemical Tests May Increase the Diagnostic Accuracy of Chromogranin A in Detecting Patients with Neuroendocrine Tumors
Introduction: Serum chromogranin A (CgA) may be falsley increased in patients with renal impairment and systemic inflammation.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: MD, PhD Ivan Kruljac
#1636 Preoperative Blood Neutrophil-To-Lymphocyte Ratio-Based Nomogram Predicts Lymph Node Metastasis in Patients of Resectable Pancreatic Neuroendocrine Tumors
Introduction: Neutrophil-to-lymphocyte ratio(NLR) is one of the systemic inflammation markers, which has prognostic values in many types of tumor. However, hardly no research has reported the relationship between NLR and pancreatic neuroendocrine tumors(panNETs).
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Zhou Tong
Authors: Tong Z, Liu L, Zheng Y, Jiang W, ...
#2203 A Case of Rectal Abscess Emerged Immediately after Starting Chemotherapy with Everolimus and Required Surgical Drainage
Introduction: <Introduction>Everolimus is widely used for unresectable panNET. For its efficacy as an immunosuppressant, infectious adverse events are well-known.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Kenzo Nakano
Authors: Nakano K, Masui T, Yogo A, Uchida Y, ...
#1308 Systemic Treaments and Prognostic Factors in Chinese Patients with Progressive Advanced Well-differentiated Pancreatic Neuroendocrine Tumors
Introduction: Patients with well-differentiated pancreatic neuroendocrine tumors (pNETs) often present with metastatic disease at the time of diagnosis when curative surgery is not feasible. A variety of systemic therapeutic options exist, but the best strategy is still unknown.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Others
Presenting Author: Yuejuan Cheng
Authors: Cheng Y, Gao H, Bai C M, Ying H, ...
#2161 Outcomes of Locoregional Treatment for Unifocal Progression in Widespread Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Introduction: New systemic treatments have improved the therapeutic landscape for patients with progressive, metastatic GEP-NETs. While drugs such as everolimus are appropriate for patients with widespread disease progression, local treatment approaches may be more appropriate for patients with unifocal progression.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Taymeyah Al-Toubah
Authors: Al-Toubah T, Cives M, Anaya D, Soares H, ...
#632 Strategy of Combining Liver-directed Local Treatment with Systemic Treatment in Patients with Liver Metastasis of Neuroendocrine Tumor
Introduction: Little is known about the clinical outcomes of liver-directed local treatment (tx) in combination with systemic tx in patients with liver metastasis of neuroendocrine tumor (NET).
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Professor Do-Youn Oh
Authors: Kim S, Kim J, Han S, Oh D Y, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.